vTv Therapeutics (NASDAQ:VTVT – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect vTv Therapeutics to post earnings of ($1.07) per share and revenue of $0.33 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). On average, analysts expect vTv Therapeutics to post ($2.35) EPS for the current fiscal year and ($4.53) EPS for the next fiscal year.
vTv Therapeutics Stock Down 4.1%
NASDAQ VTVT opened at $24.15 on Tuesday. vTv Therapeutics has a 52 week low of $20.23 and a 52 week high of $44.00. The firm has a market cap of $95.15 million, a PE ratio of -22.78 and a beta of 0.21. The business’s fifty day simple moving average is $30.10 and its 200-day simple moving average is $33.51.
Analyst Ratings Changes
A number of analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. HC Wainwright reduced their price target on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. BTIG Research reiterated a “buy” rating and issued a $57.00 target price on shares of vTv Therapeutics in a report on Wednesday, October 14th. Lifesci Capital raised shares of vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Finally, Wall Street Zen lowered vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $55.83.
View Our Latest Analysis on VTVT
About vTv Therapeutics
vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.
Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.
Further Reading
- Five stocks we like better than vTv Therapeutics
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
